Bioanalysis of MMR and KRAS - a key factor in diagnosis of colorectal cancer.

Two miniaturized electrochemical devices were designed for the simultaneous bioanalysis of MMR (MLH1, MSH2, MSH6, PMS2), and of KRAS in whole blood, urine, saliva, and tumoral tissues. The devices comprised besides the electronic part of the potentiostat a combined 3D stochastic microsensor (combined microplatform) with the sensing part based on the modification of graphene decorated with nitrogen, sulfur and boron (NSB-EGR) modified with two types of frutafit: FTEX and FHD. For the assay of MSH2, MSH6, KRAS, and PMS2 higher sensitivities were recorded when the microdevice based on FHD was used, while for the assay of MLH1 the best sensitivity was achieved by using the microdevice based on FTEX. While the limits of quantification for MLH1, MSH2, and PMS2 were not influenced by the modifier, the microdevice based on FHD provided the lowest limit of quantification for KRAS, the microdevice based on FTEX provided the lowest limit of quantification for MSH6. The validation tests performed proved that recoveries of MLH1, MSH2, MSH6, PMS2, and of KRAS in whole blood, urine, saliva, and tumoral tissues higher than 98.50% with RSD (%) values lower than 0.10% were recorded. This journal is © The Royal Society of Chemistry.

Citation

Raluca-Ioana Stefan-van Staden, Alexandru Adrian Bratei, Ruxandra-Maria Ilie-Mihai, Damaris-Cristina Gheorghe, Bianca Maria Tuchiu, Simona Gurzu. Bioanalysis of MMR and KRAS - a key factor in diagnosis of colorectal cancer. RSC advances. 2023 Aug 04;13(34):24086-24092

PMID: 37577090

search → result